Discover why Rigel Pharma (RIGL) is a contrarian biotech BUY with surging revenues, strong drug sales, and 20-30% upside ...

Shares U.S. Pharmaceuticals ETF offers growth and dividends from top holdings like LLY, JNJ, MRK with strong earnings and ...

And the best news is that it likely still has plenty of upside potential. Given its current momentum, Eli Lilly could even ...

Ascendis Pharma (ASND) has delivered some interesting performance numbers lately, with the stock climbing over 9% in the past 3 months and more than 53% year to date. This recent momentum has caught ...

Previous mega blockbusters took years to reach their peak sales. Lilly’s tirzepatide franchise is on course to exceed them ...

CDMO-linked chemical makers are pulling ahead as tariff shocks, Chinese oversupply, and weak global demand hit the broader ...

Of the 34 listed companies in the sector, 23 have so far disclosed their first-quarter results. Fourteen of these firms posted year-on-year profit growth, six reported declines, while three slipped ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) will host an Investor Day in New York City today. Senior executives will provide an update on the company’s plans to ...

Indian healthcare is entering a new growth cycle, with hospitals and CDMO players expected to deliver strong 20% EBITDA CAGR, ...

Royalty Pharma reports strong Q4 and FY 2024 financial growth, with projected 2025 Portfolio Receipts between $2.9 and $3.05 billion. Royalty Pharma plc reported strong financial results for Q4 2024 ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter ...

ZURICH (Reuters) -Switzerland's economy contracted by 0.5% in the third quarter when adjusted for sporting events, driven by lower exports in the chemical and pharmaceutical industry, the economy ...